Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation

Cytokine
Toru YagoShigeru Kotake

Abstract

Tacrolimus (FK506, Prograf®) is an orally available, T cell specific and anti-inflammatory agent that has been proposed as a therapeutic drug in rheumatoid arthritis (RA) patients. It has been known that T cells have a critical role in the pathogenesis of RA. Recent studies suggest that Th17 cells, which mainly produce IL-17, are involved in many autoimmune inflammatory disease including RA. The present study was undertaken to assess the effect of tacrolimus on IL-17-induced human osteoclastogenesis and human Th17 differentiation. Human CD14(+) monocytes were cultured in the presence of macrophage-colony stimulating factor (M-CSF) and IL-17. From day 4, tacrolimus was added to these cultures. Osteoclasts were immunohistologically stained for vitronectin receptor 10days later. IL-17 production from activated T cells stimulated with IL-23 was measured by enzyme-linked immunosorbent assay (ELISA). Th17 differentiation from naïve T cells was assayed by flow cytometry. Tacrolimus potently inhibited IL-17-induced osteoclastogenesis from human monocytes and osteoclast activation. Addition of tacrolimus also reduced production of IL-17 in human activated T cells stimulated with IL-23. Interestingly, the population of human IL-17(+)IFN-...Continue Reading

References

Sep 14, 2002·Annals of the Rheumatic Diseases·R L Van BezooijenC W G M Löwik
Nov 8, 2006·The Journal of Experimental Medicine·Kojiro SatoHiroshi Takayanagi
May 9, 2007·Nature Immunology·Eva V Acosta-RodriguezGiorgio Napolitani
Aug 7, 2007·Nature Immunology·Nicholas J WilsonRene de Waal Malefyt
Sep 1, 2007·Arthritis and Rheumatism·Zhi ChenJohn J O'Shea
Oct 31, 2009·Arthritis and Rheumatism·Shigeru KotakeHisashi Yamanaka
Jun 29, 2010·Arthritis and Rheumatism·Jan LeipeAlla Skapenko

❮ Previous
Next ❯

Citations

May 8, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose F Camargo, Shahid Husain
Apr 27, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Debbie M RoeleveldMarije I Koenders
Oct 23, 2015·Journal of Cellular Physiology·Sara SprangersTeun J de Vries
Jul 11, 2012·Journal of Cellular Physiology·Guangwei Liu, Hui Yang
Feb 15, 2018·Proceedings of the National Academy of Sciences of the United States of America·Kyoko HashimotoShingo Sato
Sep 27, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mohammed-Amine El AzreqFawzi Aoudjit
Mar 6, 2019·BMC Complementary and Alternative Medicine·Kyoung Chan DohChul Woo Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.